|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Sumitomo_Dainippon_Pharma
|
|
gptkbp:CEO
|
David_Marek
|
|
gptkbp:clinicalTrials
|
Phase 1
Phase 2
Phase 3 trials
|
|
gptkbp:collaborations
|
gptkb:National_Institutes_of_Health
academic institutions
research organizations
clinical development
|
|
gptkbp:communityEngagement
|
research communities
patient advocacy groups
healthcare_professionals
|
|
gptkbp:focus
|
oncology
women's health
|
|
gptkbp:founded
|
2016
|
|
gptkbp:funding
|
Series B
Series C
IPO
|
|
gptkbp:headquarters
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Myovant Sciences
|
|
gptkbp:investmentFocus
|
venture capital
|
|
gptkbp:leadership
|
board of directors
scientific advisory board
|
|
gptkbp:location
|
gptkb:Japan
gptkb:United_States
Europe
|
|
gptkbp:market
|
gptkb:Asia
gptkb:North_America
Europe
|
|
gptkbp:mission
|
improve women's health
advance oncology treatments
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:Pfizer
|
|
gptkbp:products
|
Myfembree
Relugolix
Orgovyx
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
EMA
|
|
gptkbp:researchFocus
|
prostate cancer
endometriosis
uterine fibroids
|
|
gptkbp:stockSymbol
|
MYOV
|
|
gptkbp:subsidiary
|
Myovant_Sciences_GmbH
|
|
gptkbp:tradedOn
|
gptkb:NYSE
|
|
gptkbp:tributaryOf
|
hormonal therapies
non-hormonal therapies
|
|
gptkbp:vision
|
transforming care for patients
|
|
gptkbp:website
|
myovant.com
|